ARTICLE | Clinical News
Novartis' secukinumab meets in Phase III
September 26, 2014 3:20 AM UTC
Novartis AG (NYSE:NVS;SIX:NOVN) said secukinumab ( AIN457) met the primary endpoint of improving ACR20 response rate in two Phase III studies to treat psoriatic arthritis. Full trial results will be presented at an upcoming medical meeting. ...